Rates of overweight and obesity in the United States have doubled in the last 30 years. The rise of obesity has been deemed a crisis requiring urgent action. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are now being used for weight loss, showing significant efficacy. Different obesity phenotypes have been identified to determine the best responders to GLP-1 RAs. Concerns about potential side effects of GLP-1 RAs have emerged, including gastrointestinal issues and the risk of certain diseases. Patients should combine GLP-1 RAs with lifestyle changes for optimal results. Despite their popularity, many Americans are hesitant to use injectable weight loss medications like GLP-1 RAs.
Source link
As GLP-1 Use Surges, Clinicians Weigh Benefits and Risks
